A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer (Q41560445)

3 October 2017

A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer (English)

1 reference

3 October 2017

1 reference

1 reference

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Takashi Sato

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Kenzo Soejima

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Katsuhiko Naoki

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Kota Ishioka

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Morio Nakamura

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Michie Nakatani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Ichiro Kawada

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Hideo Watanabe

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Ichiro Nakachi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Hiroyuki Yasuda

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Ryosuke Satomi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Sohei Nakayama

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Sinnosuke Ikemura

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Hideki Terai

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Keiko Ohgino

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Daisuke Arai

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Tetsuo Tani

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Aoi Kuroda

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Makoto Nishino

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Tomoko Betsuyaku

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

7 January 2015

1 reference

Cancer Chemotherapy and Pharmacology

3 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

513-519

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563719%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-014-2673-8

13 June 2020

exact match

0 references

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2673-8